309 related articles for article (PubMed ID: 21809367)
21. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
22. Integrating novel therapies in the transplant paradigm.
Harousseau JL
Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
24. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
25. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
26. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
[TBL] [Abstract][Full Text] [Related]
27. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
28. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
29. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
30. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
31. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Zeng Z; Lin J; Chen J
Ann Hematol; 2013 Jul; 92(7):935-43. PubMed ID: 23455401
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Krejci M; Scudla V; Tothova E; Schutzova M; Koza V; Adam Z; Krivanova A; Pour L; Buchler T; Sandecka V; Kralova D; Zahradova L; Vorlicek J; Mayer J; Hajek R
Clin Lymphoma Myeloma; 2009 Dec; 9(6):436-42. PubMed ID: 19951883
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
35. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
36. Initial treatment of transplant candidates with multiple myeloma.
Moreau P; Touzeau C
Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
[TBL] [Abstract][Full Text] [Related]
37. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
van de Velde H; Londhe A; Ataman O; Johns HL; Hill S; Landers E; Berlin JA
Eur J Haematol; 2017 Mar; 98(3):269-279. PubMed ID: 27859769
[TBL] [Abstract][Full Text] [Related]
38. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
40. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
